
Opinion|Videos|April 4, 2024
Allocation of Investment and Value-Based Arrangements in Diabetes Care
Insights on how payers can allocate their resources to best improve outcomes for patients with diabetes.
Advertisement
Episodes in this series

Advertisement
Related to this article

NeosRx CEO Jeff Dunn, Pharm.D., MBA, explains how 340B claims can disadvantage PBMs because of loss of rebates..

Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.

A mouse study found that how much antigen sits on a vaccine’s surface, not just its size or shape, drives the T-cell response.

Out-of-pocket costs may affect more than patients’ wallets, raising anticipated pain and discouraging some from scheduling care, according to a new study out of Carnegie Mellon University.

The FDA cleared Teva’s Igalmi sublingual film for at-home use, the first at-home approved option for agitation tied to schizophrenia or bipolar disorder.

A system can cover its population and still struggle with access, workforce capacity and the cost of care

Drug launch prices are rising, but Benjamin N. Rome, M.D., M.P.H., and colleagues found no evidence manufacturers raised them in response to the Inflation Reduction Act.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Bronchiectasis is more common in the U.S. than a decade ago, study finds
2
FDA approves Igalmi for at-home use for agitation in schizophrenia and bipolar disorder
3
More antigen on a cancer vaccine meant more tumor-fighting T cells in mice
4
Quick Q&A: Jeff Dunn, Pharm.D., MBA, on 340B discounts and PBM rebates
5



